Ireland
--:--IST
Priya Life Science Medicines & markets
England & United States · NHSBSA and CMS public data · By medicine

What health systems spend on each medicine

The cost of every medicine dispensed in the community in England, and every drug reimbursed by US Medicaid, from the two systems' own published data.

Sources: NHSBSA Prescription Cost Analysis (Open Government Licence v3.0); CMS State Drug Utilization Data and FDA NDC Directory (US public domain). NHS to Jul 2026 · Medicaid 2025
£11.89bnNHS England medicines and appliances, Aug 2025 to Jul 2026 (+6.6% on the 12 months before)
1.31bnPrescription items dispensed in England, same 12 months
$111.94bnPaid by US Medicaid for outpatient drugs in 2025, before rebates (+8.2% on 2024)
725mMedicaid prescriptions in 2025

NHS England spent £11.89bn on medicines and appliances dispensed in the community from Aug 2025 to Jul 2026, +6.6% on the previous 12 months, at list price before discounts. Tirzepatide cost the most, at £795.3m, and the ten costliest items took 22.6% of the total. US Medicaid paid $111.94bn for outpatient drugs in 2025 before manufacturer rebates, led by semaglutide (Ozempic, Wegovy, Rybelsus) at $6.50bn. Both figures are gross: neither system publishes the discounts and rebates it receives per drug.

Showing medicines matching “Omeprazole”: 2 in England, 5 in Medicaid (first 100 of each).

01

NHS England: cost by medicine

Aug 2025 to Jul 2026, net ingredient cost
#Medicine (BNF chemical substance)Cost, 12 monthsChangeItemsCost per item
Omeprazole
Gastro-Intestinal System
£98.5m -2.8% 35,214,426 £2.80
Esomeprazole
Gastro-Intestinal System
£14.7m +16.9% 2,922,865 £5.02

Net ingredient cost is the list price of what was dispensed, before discounts, fees and patient charges. It covers prescriptions dispensed in the community in England, including appliances such as glucose sensors and catheters, not hospital medicines. Where the BNF moved products to a new code during the year, no change is shown because the two periods count different products. Cost per item is calculated here.

02

US Medicaid: spending by drug

2025, amount Medicaid reimbursed
#Drug (active ingredient)Medicaid paid, 2025Change on 2024PrescriptionsPer prescription
Omeprazole
Omeprazole, Prilosec, omeprazole, Acid Reducer
$91.8m -6.3% 8,770,936 $10.47
Esomeprazole magnesium
Nexium, Esomeprazole Magnesium, Esomeprazole magnesium, Esomeprazole Magnesium
$53.5m -4.7% 699,134 $76.53
Omeprazole and sodium bicarbonate
Konvomep, Omeprazole/Sodium Bicarbonate, Zegerid, Omeprazole and Sodium Bicarbonate
$20.4m -44.0% 50,010 $408.50
Omeprazole magnesium, amoxicillin and rifabutin
Talicia
$5.2m +17.5% 6,569 $795.74
Naproxen and esomeprazole magnesium
Naproxen and esomeprazole magnesium
$1.0m -83.2% 3,209 $324.37

The amount Medicaid reimbursed pharmacies for outpatient drugs, national totals from all states, before the manufacturer rebates Medicaid receives (CMS does not publish rebates per drug). Rows CMS suppresses because they cover fewer than 11 prescriptions are left out. Products are grouped by active ingredient using the FDA NDC Directory, which named 99.4% of the spending; the rest keeps CMS's short product name and is only in the product totals. Cost per prescription is calculated here.

Medicines data, weekly

One email every Friday: new approvals, shortages, spending and trial registrations, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Every amount is the sum of the source's own published figures. Contains public sector information licensed under the Open Government Licence v3.0 (NHSBSA). Changes, shares and costs per item or prescription are calculated here and labelled.

A job downloads both datasets every week, sums them by medicine and keeps the previous version if either source fails or returns far fewer medicines than before. No AI drafting and no editorial pass. See our methodology. The NHSBSA and CMS data on this page was last retrieved on 8 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.